Philip Lister

3.3k total citations · 1 hit paper
50 papers, 2.6k citations indexed

About

Philip Lister is a scholar working on Molecular Medicine, Pharmacology and Epidemiology. According to data from OpenAlex, Philip Lister has authored 50 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Molecular Medicine, 22 papers in Pharmacology and 13 papers in Epidemiology. Recurrent topics in Philip Lister's work include Antibiotic Resistance in Bacteria (30 papers), Antibiotics Pharmacokinetics and Efficacy (21 papers) and Pneumonia and Respiratory Infections (10 papers). Philip Lister is often cited by papers focused on Antibiotic Resistance in Bacteria (30 papers), Antibiotics Pharmacokinetics and Efficacy (21 papers) and Pneumonia and Respiratory Infections (10 papers). Philip Lister collaborates with scholars based in United States, United Kingdom and China. Philip Lister's co-authors include Daniel J. Wolter, Nancy D. Hanson, Christine C. Sanders, Laurel C. Preheim, Martha J. Gentry, J. Michael Janda, Richard V. Goering, Annpey Pong, Stephen A. Chartrand and William E. Sanders and has published in prestigious journals such as Clinical Microbiology Reviews, Clinical Infectious Diseases and Journal of Clinical Microbiology.

In The Last Decade

Philip Lister

47 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Antibacterial-ResistantPseudomonas aeruginosa: Clinical Impact and Complex Regulation of Chromosomally Encoded Resistance Mechanisms

2009 1.4k citations Philip Lister, Daniel J. Wolter et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Philip Lister United States	24	1.7k	985	853	591	368	50	2.6k
Antonio Oliver Spain	24	1.8k 1.1×	973 1.0×	655 0.8×	390 0.7×	359 1.0×	39	2.2k
Laura Zamorano Spain	30	2.3k 1.4×	1.2k 1.2×	935 1.1×	494 0.8×	457 1.2×	67	2.9k
Gabriel Cabot Spain	33	2.6k 1.5×	1.4k 1.5×	957 1.1×	450 0.8×	564 1.5×	57	3.1k
Xavier Mulet Spain	22	1.6k 1.0×	890 0.9×	620 0.7×	283 0.5×	437 1.2×	34	1.9k
Bartolomé Moyá Spain	32	2.7k 1.6×	1.3k 1.4×	1.1k 1.2×	586 1.0×	446 1.2×	51	3.2k
Thomas D. Gootz United States	36	1.5k 0.9×	1.3k 1.3×	1.2k 1.4×	661 1.1×	160 0.4×	60	3.4k
Katy Jeannot France	29	1.9k 1.1×	1.1k 1.1×	555 0.7×	290 0.5×	255 0.7×	73	2.4k
Mariagrazia Perilli Italy	27	1.8k 1.0×	776 0.8×	543 0.6×	427 0.7×	262 0.7×	110	2.6k
Carla López-Causapé Spain	21	1.6k 0.9×	982 1.0×	445 0.5×	264 0.4×	356 1.0×	69	2.0k
Katherine Young United States	35	2.2k 1.3×	845 0.9×	1.7k 2.0×	704 1.2×	869 2.4×	117	3.7k

Countries citing papers authored by Philip Lister

Since Specialization

Citations

This map shows the geographic impact of Philip Lister's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip Lister with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip Lister more than expected).

Fields of papers citing papers by Philip Lister

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip Lister. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip Lister. The network helps show where Philip Lister may publish in the future.

Co-authorship network of co-authors of Philip Lister

This figure shows the co-authorship network connecting the top 25 collaborators of Philip Lister. A scholar is included among the top collaborators of Philip Lister based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip Lister. Philip Lister is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lister, Philip, et al.. (2013). Effect of drug treatment options on the mobility and expression of blaKPC. Journal of Antimicrobial Chemotherapy. 68(12). 2779–2785. 5 indexed citations

Roth, Amanda L., Kenneth S. Thomson, Philip Lister, & Nancy D. Hanson. (2012). Production of KPC-2 Alone Does Not Always Result in β-Lactam MICs Representing Resistance in Gram-Negative Pathogens. Journal of Clinical Microbiology. 50(12). 4183–4184. 4 indexed citations

Wolter, Daniel J. & Philip Lister. (2012). Mechanisms of β-lactam Resistance Among Pseudomonas aeruginosa. Current Pharmaceutical Design. 19(2). 209–222. 64 indexed citations

Wolter, Daniel J., Jennifer Ann Black, Philip Lister, & Nancy D. Hanson. (2009). Multiple genotypic changes in hypersusceptible strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients do not always correlate with the phenotype. Journal of Antimicrobial Chemotherapy. 64(2). 294–300. 33 indexed citations

Lister, Philip. (2007). Carbapenems in the USA: focus on doripenem. Expert Review of Anti-infective Therapy. 5(5). 793–809. 29 indexed citations

Lister, Philip, et al.. (2006). Levofloxacin/imipenem prevents the emergence of high-level resistance among Pseudomonas aeruginosa strains already lacking susceptibility to one or both drugs. Journal of Antimicrobial Chemotherapy. 57(5). 999–1003. 29 indexed citations

Lister, Philip & Daniel J. Wolter. (2005). Levofloxacin-Imipenem Combination Prevents the Emergence of Resistance among Clinical Isolates of Pseudomonas aeruginosa. Clinical Infectious Diseases. 40(Supplement_2). S105–S114. 39 indexed citations

Lister, Philip. (2005). The role of pharmacodynamic research in the assessment and development of new antibacterial drugs. Biochemical Pharmacology. 71(7). 1057–1065. 15 indexed citations

Wolter, Daniel J., et al.. (2004). Multidrug resistance associated with mexXY expression in clinical isolates of Pseudomonas aeruginosa from a Texas hospital. Diagnostic Microbiology and Infectious Disease. 50(1). 43–50. 59 indexed citations

10.

Lister, Philip. (2002). Chromosomally-Encoded Resistance Mechanisms of Pseudomonas aeruginosa. PubMed. 2(4). 235–243. 20 indexed citations

11.

Lister, Philip. (2001). Pharmacodynamics of Moxifloxacin and Levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an In Vitro Pharmacodynamic Model. Clinical Infectious Diseases. 32(Supplement_1). S33–S38. 38 indexed citations

12.

Lister, Philip. (2001). Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy. 47(6). 811–818. 49 indexed citations

13.

Lister, Philip. (2000). β‐Lactamase Inhibitor Combinations with Extended‐Spectrum Penicillins: Factors Influencing Antibacterial Activity against Enterobacteriaceae and Pseudomonas aeruginosa. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 20(9P2). 213S–218S; discussion 224S. 25 indexed citations

14.

Lister, Philip & Christine C. Sanders. (1999). Pharmacodynamics of Trovafloxacin, Ofloxacin, and Ciprofloxacin against Streptococcus pneumoniae in an In Vitro Pharmacokinetic Model. Antimicrobial Agents and Chemotherapy. 43(5). 1118–1123. 67 indexed citations

15.

Lister, Philip & Christine C. Sanders. (1999). Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy. 43(1). 79–86. 120 indexed citations

16.

Lister, Philip, William E. Sanders, & Christine C. Sanders. (1998). Cefepime-Aztreonam: a Unique Double β-Lactam Combination for Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 42(7). 1610–1619. 30 indexed citations

17.

Lister, Philip, Annpey Pong, Stephen A. Chartrand, & Christine C. Sanders. (1997). Rationale behind high-dose amoxicillin therapy for acute otitis media due to penicillin-nonsusceptible pneumococci: support from in vitro pharmacodynamic studies. Antimicrobial Agents and Chemotherapy. 41(9). 1926–1932. 39 indexed citations

18.

Lister, Philip, Martha J. Gentry, & Laurel C. Preheim. (1993). Granulocyte Colony-Stimulating Factor Protects Control Rats but Not Ethanol-Fed Rats from Fatal Pneumococcal Pneumonia. The Journal of Infectious Diseases. 168(4). 922–926. 32 indexed citations

19.

Lister, Philip, Martha J. Gentry, & Laurel C. Preheim. (1993). Ethanol Impairs Neutrophil Chemotaxis In Vitro but Not Adherence or Recruitment to Lungs of Rats with Experimental Pneumococcal Pneumonia. The Journal of Infectious Diseases. 167(5). 1131–1137. 27 indexed citations

20.

Clark, Richard B., Philip Lister, & J. Michael Janda. (1991). In vitro susceptibilities of Edwardsiella tarda to 22 antibiotics and antibiotic-β-lactamase-inhibitor agents. Diagnostic Microbiology and Infectious Disease. 14(2). 173–175. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact